Physician profile
Daisy Bang
NPI 1356579460
$2,931.55
in general payments reported to CMS, 2019-2025
15 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $643 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,055.73 | 2024-2025 | |
| Janssen Biotech, INC. | $343.24 | 2024-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $303.97 | 2024-2025 | Acthar |
| Ucb, INC. | $287.08 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $201.07 | 2024-2025 | Zepbound, Taltz |
| Novartis Pharmaceuticals Corporation | $138.83 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.71 | 2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $107.76 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $102.53 | 2024-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $100.45 | 2024-2025 | Benlysta |
| Genzyme Corporation | $84.13 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $34.91 | 2024-2025 | Orencia |
| Sandoz INC. | $23.62 | 2024 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $19.19 | 2025 | Opsynvi |
| Invivyd INC | $18.33 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Bang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.